| # | Country | Total Patents | |
|---|---|---|---|
| #1 | United States | 6 | |
| #2 | New Zealand | 5 | |
| #3 | Australia | 2 | |
| #4 | China | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology | |
| #3 | Measurement | |
| #4 | Environmental technology | |
| #5 | Machines |
| # | Technology | |
|---|---|---|
| #1 | Medical preparations | |
| #2 | Peptides | |
| #3 | Therapeutic chemical compounds | |
| #4 | Microorganisms | |
| #5 | Analysing materials | |
| #6 | Climate change adaptation technologies | |
| #7 | Unspecified technologies |
| # | Name | Total Patents |
|---|---|---|
| #1 | Itoh Kyogo | 12 |
| #2 | Imai Yasuhisa | 6 |
| #3 | Shichijo Shigeki | 6 |
| #4 | Gomi Shinya | 2 |
| #5 | Nakao Masanobu | 2 |
| #6 | Kobayashi Terutada | 1 |
| #7 | Shigeki Shichijo | 1 |
| #8 | Yasuhisa Imai | 1 |
| #9 | Tho Uhi | 1 |
| #10 | Kyogo Itoh | 1 |
| Publication | Filing date | Title |
|---|---|---|
| US6664232B1 | HLA-A2 restraint tumor antigen peptide originating in SART-1 | |
| NZ509284A | Tumour antigen peptide derived from SART-that binds to HLA-A24 antigen thereby facilitating recognition by a T call | |
| US6555652B1 | Tumor antigen peptide derivatives | |
| AU4966797A | Human cancer regression antigen protein |